Depression Has a Gut Signature: 66 Studies Point to the Same Bacteria

If you have ever wondered whether your gut and your mood are more connected than your doctor lets on, a new review of the evidence suggests you are onto something real. Researchers pooled 66 human studies on gut bacteria in people with major depressive disorder (MDD) and found the same pattern showing up again and again: a shortage of certain calming, inflammation-taming bacteria and a surplus of others linked to inflammation. The review does not prove gut bacteria cause depression, but it lays out a plausible, repeatedly observed biological pathway from the gut to the brain, one that a self-directed reader managing depression or a co-occurring gut condition may want to understand.

Key takeaways:

• Across 66 studies, people with major depressive disorder consistently had less Faecalibacterium, Roseburia, and Coprococcus, bacteria that produce short-chain fatty acids (SCFAs, compounds that help maintain the gut's protective lining) and more Eggerthella, Alistipes, Streptococcus, and Proteobacteria, taxa linked to inflammation.
• The proposed mechanism: depleted SCFA-producing bacteria weaken the gut barrier ("leaky gut"), letting bacterial toxins and inflammatory molecules leak into the bloodstream and eventually the brain.
• Depression and anxiety are far more common in people who also have inflammatory bowel disease, up to 58% of patients during active ulcerative colitis flares, underscoring the gut-brain overlap.
• The evidence in humans is correlational, not proof of cause and effect. Animal transplant studies offer some causal support, but no probiotic, diet, or supplement is yet proven to treat depression in people.

A Consistent Gut Bacteria Pattern Shows Up in Depression

Reviewing 66 published studies on adults with major depressive disorder (MDD), researchers identified a reproducible pathobiological pattern (a disease-linked biological signature): depletion of protective, short-chain fatty acid-producing bacteria alongside overgrowth of bacteria linked to inflammation. The most consistently depleted genus was Faecalibacterium, reported as significantly reduced in roughly 24 of the 66 studies, across both Asian and European cohorts. Similar, if less consistent, reductions appeared for Roseburia, Coprococcus, and the Lachnospiraceae family, all producers of butyrate and other short-chain fatty acids (SCFAs) that help maintain the gut lining. On the other side, Eggerthella, Alistipes, Streptococcus, and the bacterial phylum Proteobacteria were repeatedly found in greater abundance in people with depression across multiple independent cohorts.

Why This Matters if You Have Depression, IBS, or IBD

The review is written for a population that shows up in the data too: people whose depression overlaps with a gut condition. Anxiety and depression affect an estimated 28.81% and 33.90%, respectively, of the general inflammatory bowel disease (IBD) population, and those rates climb sharply during flares, with depression reported in 58% and anxiety in 50% of patients during active ulcerative colitis. The authors argue this is not a coincidence: the same dysbiosis (an imbalanced gut microbial community) that shows up in depression research also drives gut barrier breakdown and systemic inflammation, which could help explain why mood symptoms and gut symptoms so often travel together.

How the Review Was Done

The authors searched PubMed and Scopus for clinical studies of gut microbiota composition in adults ages 18 to 65 with a confirmed MDD diagnosis, following PRISMA systematic review guidelines with a three-person independent screening process. Of 915 records initially identified (274 from PubMed, 641 from Scopus), 44 duplicates were removed, leaving 871 unique articles for title and abstract screening; a final set of 66 studies met all inclusion criteria and were synthesized. The review excluded animal studies, pediatric and geriatric populations, and people with bipolar disorder, keeping the focus on adult MDD specifically.

What This Could Mean for Managing Your Own Health

None of this means a stool test can currently diagnose depression, or that a supplement can treat it. The review's own conclusion is blunt: interventions like dietary changes, prebiotics, probiotics, psychobiotics, synbiotics, or fecal microbiota transplantation (FMT, transferring gut bacteria from a donor) have shown only modest, preliminary improvements in depressive symptoms and are "not yet ready for standard clinical practice." What is worth discussing with a doctor, especially if you also have IBS or IBD, is that gut symptoms and mood symptoms may be mechanistically linked rather than coincidental, and that antidepressants themselves, particularly SSRIs like fluoxetine, sertraline, escitalopram, and paroxetine, can directly alter gut bacterial composition, which the researchers flag as an important confounder in this entire body of research.

What the Review Cannot Establish

Because almost all of the underlying 66 studies compared gut bacteria at a single point in time, the review cannot say whether gut dysbiosis causes depression, results from it, or both. The authors describe the relationship as likely bidirectional: chronic stress, diet, sleep, and reduced activity that accompany depression can all reshape gut bacteria, while gut dysbiosis may independently promote depressive symptoms through inflammation and barrier breakdown. The strongest support for a causal, gut-to-brain direction comes not from the human studies but from animal research: transplanting fecal microbiota from people with MDD into germ-free or microbiota-depleted rodents induced depression-like behaviors, increased neuroinflammation, and impaired hippocampal neurogenesis (the growth of new neurons in a brain region tied to mood) in those animals. The review also notes substantial heterogeneity across the human studies, in diet, geography, antidepressant use, and sequencing methods, that likely explains why some bacteria (including Bacteroides, Blautia, and Bifidobacterium) showed inconsistent results from study to study.

What Comes Next

The authors call for larger, longitudinal studies that track gut bacteria and depressive symptoms over time in the same people, standardized methodology across labs, and designs that explicitly account for antidepressant use as a confounder, arguing this is necessary before microbiome-based diagnostics or therapies for depression can be considered clinically reliable.

Common Questions

Do gut bacteria cause depression, or does depression change gut bacteria? The review cannot answer that from human data alone, since almost all the underlying studies are a single snapshot, not a before-and-after comparison. It leans toward a two-way relationship, though rodent experiments where transplanted "depressed" gut bacteria triggered depression-like behavior offer the clearest evidence for a gut-to-brain causal direction.

Can probiotics treat depression? Not based on current evidence. The review found only modest, preliminary results for probiotics, prebiotics, and similar interventions, and its authors explicitly say these are not ready for standard clinical use.

What is "leaky gut" and how does it relate to mood? It refers to a weakened intestinal barrier that lets bacterial components like lipopolysaccharide (LPS, a molecule from bacterial cell walls) leak into the bloodstream, triggering inflammation that can reach the brain and disrupt neurotransmitter pathways involved in mood.

Should I get a microbiome test if I have depression? This review does not support using a microbiome test to diagnose or guide treatment for depression; the bacterial patterns it describes are population-level trends, not an individual diagnostic tool.

References

Kalina Światlak, Wiktoria Żelazna, Justyna Trzaskalik (2026). Melancholy in the Microbiome: Decoding the Gut-Brain Axis in Major Depression – A Systematic Review. Journal of Education, Health and Sport. https://doi.org/10.12775/jehs.2026.95.74083